13th December 2012
Press interviews with Dr Glenn Crocker from midday at Queen Elizabeth II Conference Centre, Westminster, London, UK
An optimistic picture of the UK life sciences sector emerges from today’s publication of the annual UK Life Sciences start-up report. The 291 new firms launched in the study period represent the next generation of growth-focussed firms, born at the dawn of a new era for the bioscience and life science sector.
BioCity’s XenoGesis has formed a strategic alliance with US-based XenoTech to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early drug discovery through development and beyond.
Together, XenoGesis and XenoTech aim to provide collaborative, integrated and rational approaches to DMPK studies within the ever-evolving framework of drug discovery and development. Their combined consultative approach to problem solving leads to increased flexibility, high content and quality, and ultimately time- and cost-savings. The influence of DMPK is paramount for successful drug development, as these factors ultimately affect drug efficacy and safety. A holistic approach is crucial and serves as the foundation of this strategic alliance.
XenoTech Ltd is a contract research organisation (CRO), serving clients with their experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes. They offer a variety of in vitro contract studies for drug candidate evaluation, as well as an expensive selection of products for drug metabolism research.
Just four months into trading from its Nottingham UK base, XenoGesis Limited has exceeded its initial sales targets by more than 300%. The BioCity Nottingham contract research organisation began trading in early November and was providing laboratory-based drug analysis services to major global pharmaceutical clients from day one.
Started by former Associate Principal Scientist in drug metabolism & pharmacokinetics (DMPK) at AstraZeneca Dr Richard Weaver, the company has also attracted £135,000 investment to enable the purchase of laboratory and IT equipment and to support its marketing activities. The company already employs two senior scientists, Dr Manfred Ismair and Dawn Parkins who worked with Dr Weaver in AstraZeneca, and is set to take on an Associate research scientist in April.
The encouraging sales achievements are the result of several international visits as well as Dr Weaver’s considerable reputation in the pharmaceutical sector. XenoGesis specialises in pre-clinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Their laboratory tests demonstrate how the human body might affect the way a drug behaves. Backing this up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’ makes the XenoGesis service attractive to global drug companies.
Monday 5th March 2012
Mobius Life Sciences Fund has announced an investment in XenoGesis Limited, the contract research organisation (CRO) which provides laboratory-based services to pharmaceutical clients engaged in drug discovery. Mobius’ financing is part of a £135,000 investment round in the fast-growing start-up company, which includes loan funding from Nottingham City Council. The funds will be used for working capital and investment in both laboratory and office IT infrastructure. Mobius investment also comes with industry expertise in company growth.
Based in BioCity Nottingham, XenoGesis specialises in pre-clinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. Their laboratory tests demonstrate how the human body might affect the way a drug behaves. Backing this up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like’ makes the XenoGesis service attractive to global drug companies. Just four months since launch, the company has already signed-up several international clients.